Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy

Recruiting at 1 trial location

Overseen By M Gabra, MD

Age: 18+

Sex: Female

Trial Phase: Phase 2

Sponsor: University of Arizona

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 5 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 0

161 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing if giving a single dose of tamsulosin before surgery can help women who are having a minimally invasive hysterectomy to urinate sooner and leave the hospital faster. Tamsulosin has been studied for its effectiveness in reducing postoperative urinary retention in various surgeries.

Eligibility Criteria

Inclusion Criteria

Women 18-80 undergoing outpatient minimally invasive hysterectomy

Treatment Details

Interventions

• Placebo
• Tamsulosin

Participant Groups

Group I: Tamsulosin- intervention group Experimental Treatment 1 Intervention

Group II: Placebo group Placebo Group 1 Intervention

Tamsulosin is already approved in European Union, United States, Canada, Japan, Switzerland for the following indications:

Approved in European Union as Flomax for:

• Benign prostatic hyperplasia
• Postoperative urinary retention

Approved in United States as Flomax for:

• Benign prostatic hyperplasia
• Postoperative urinary retention

Approved in Canada as Tamsulosin for:

• Benign prostatic hyperplasia
• Postoperative urinary retention

Approved in Japan as Tamsulosin for:

• Benign prostatic hyperplasia
• Postoperative urinary retention

Approved in Switzerland as Tamsulosin for:

• Benign prostatic hyperplasia
• Postoperative urinary retention

Who Is Running the Clinical Trial?

University of Arizona

Lead Sponsor

Trials

545

Recruited

161,000+